Reuters logo
BRIEF-Biotest: impairment of US business and change of guidance
October 20, 2015 / 3:15 PM / 2 years ago

BRIEF-Biotest: impairment of US business and change of guidance

Oct 20 (Reuters) - Biotest AG :

* Announces to make impairments on Oct. 20 totalling 84 million euros ($95.26 million), leading to a negative third-quarter result (EBIT Q1-Q3 2015: -82 million euros)

* Impairment primarily relates to company’s U.S. therapy activities, including write-off of production facilities and parts of buildings in the U.S.

* Expects a significantly improved result for 4th quarter of 2015

* Is expecting an EBIT between 5 million and 10 million euros for 4th quarter of year 2015 Source text for Eikon: Further company coverage: ($1 = 0.8818 euros) (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below